Advances in pulmonary hypertension最新文献

筛选
英文 中文
What Echocardiography Can Reliably Tell Us About Our Pulmonary Hypertension Patients 超声心动图能可靠地告诉我们哪些肺动脉高压患者
Advances in pulmonary hypertension Pub Date : 2019-12-01 DOI: 10.21693/1933-088x-18.4.110
Natasha A. Vedage, A. Vaidya
{"title":"What Echocardiography Can Reliably Tell Us About Our Pulmonary Hypertension Patients","authors":"Natasha A. Vedage, A. Vaidya","doi":"10.21693/1933-088x-18.4.110","DOIUrl":"https://doi.org/10.21693/1933-088x-18.4.110","url":null,"abstract":"Pulmonary hypertension (PH) is a complex, multi-organ system disease that is broadly defined by an elevation in pulmonary artery pressures. There are key biologic differences in the pathophysiology among the different PH subgroups that warrant a targeted approach to clinical care of these patients. The complex geometry of and wide array of clinical tools to assess the right heart in PH add another layer of complexity in patient care. Echocardiography can be used as a powerful tool to discriminate among the subgroups of PH, a critical first step in evaluating a new case of PH. In this article, we will explore novel approaches using echocardiography that go beyond simply estimating pulmonary pressures and provide a readily accessible means of adding diagnostic and prognostic accuracy in the clinical setting.","PeriodicalId":92747,"journal":{"name":"Advances in pulmonary hypertension","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44137638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Pulmonary Hypertension Roundtable: The Present and Future of Imaging in Pulmonary Hypertension 肺动脉高压圆桌会议:肺动脉高压影像学的现状和未来
Advances in pulmonary hypertension Pub Date : 2019-12-01 DOI: 10.21693/1933-088x-18.4.134
{"title":"Pulmonary Hypertension Roundtable: The Present and Future of Imaging in Pulmonary Hypertension","authors":"","doi":"10.21693/1933-088x-18.4.134","DOIUrl":"https://doi.org/10.21693/1933-088x-18.4.134","url":null,"abstract":"This fall, Guest Editors Jeffrey D. Edelman, MD, Associate Professor of Medicine at the University of Washington in Seattle, and Harrison W. Farber, MD, Professor of Medicine at Tufts University School of Medicine in Boston, Massachusetts, convened a panel of experts to discuss the role of imaging in pulmonary hypertension. Guests included Benjamin H. Freed, MD, Assistant Professor of Medicine at Northwestern University Feinberg School of Medicine in Chicago, Illinois; Paul Hassoun, MD, Director of the Pulmonary Hypertension Program and Professor of Medicine at Johns Hopkins University Department of Medicine in Baltimore, Maryland; Peter Leary, MD, PhD, Associate Professor of Medicine and Director of the Pulmonary Vascular Disease Program at the University of Washington in Seattle; Sudhakar N.J. Pipavath, MD, Professor of Cardiothoracic Imaging and Adjunct Professor of Pulmonary, Critical Care, Sleep Medicine and Medicine at the University of Washington in Seattle; and Anjali Vaidya, MD, FACC, FASE, FACP, Associate Professor of Medicine and Co-Director, Pulmonary Hypertension, Right Heart Failure and CTEPH Program at Temple University in Philadelphia, Pennsylvania.","PeriodicalId":92747,"journal":{"name":"Advances in pulmonary hypertension","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46862098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ask the Expert: Radiographic Signs and Patterns of Pulmonary Hypertension: A Pictorial Essay 问专家:肺动脉高压的影像学征象和模式:一篇图片文章
Advances in pulmonary hypertension Pub Date : 2019-12-01 DOI: 10.21693/1933-088x-18.4.141
H. Carmona, Wei Wu, S. Pipavath
{"title":"Ask the Expert: Radiographic Signs and Patterns of Pulmonary Hypertension: A Pictorial Essay","authors":"H. Carmona, Wei Wu, S. Pipavath","doi":"10.21693/1933-088x-18.4.141","DOIUrl":"https://doi.org/10.21693/1933-088x-18.4.141","url":null,"abstract":"INTRODUCTION Pulmonary hypertension (PH) is a disease characterized by elevated mean pulmonary arterial pressure and/or elevated pulmonary vascular resistance, as measured by right heart catheterization. Individuals often present with dyspnea and decreased functional exertion. Imaging features of PH may be present prior to clinical diagnosis. Certain radiographic signs can be useful in identifying the etiology of the PH. We present a variety of imaging features that are aimed at making these etiologies apparent to clinicians, with a focus on those etiologies that do not otherwise usually have distinguishing clinical manifestations.","PeriodicalId":92747,"journal":{"name":"Advances in pulmonary hypertension","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47207214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Pediatric Pulmonary Hypertension on the World Stage: Do We Need Separate Neonatal Guidelines? 世界舞台上的儿童肺动脉高压:我们需要单独的新生儿指南吗?
Advances in pulmonary hypertension Pub Date : 2019-11-27 DOI: 10.21693/1933-088x-18.3.92
S. Abman, C. Galambos
{"title":"Pediatric Pulmonary Hypertension on the World Stage: Do We Need Separate Neonatal Guidelines?","authors":"S. Abman, C. Galambos","doi":"10.21693/1933-088x-18.3.92","DOIUrl":"https://doi.org/10.21693/1933-088x-18.3.92","url":null,"abstract":"In comparison with adult disease, pediatric pulmonary hypertension (PH) and related pulmonary vascular disease (PVD) remain relatively understudied and poorly understood. Despite many advances over the past decades, PH continues to cause significant morbidity and mortality in diverse neonatal, pulmonary, cardiac, hematologic, and other systemic disorders of childhood. Despite some similarities, many aspects of PH in children are distinct from adult PH. Although new drug therapies are available for off-label use in pediatric PH, the long-term outcomes of children with severe PH often remain poor. Most clinical studies have emphasized the results of clinical trials in adult patients, yet PH in pediatrics can be devastating and often contributes to poor outcomes in diverse clinical settings in newborns, infants, and children. Of several major challenges addressed in the recent 6th World Symposium on Pulmonary Hypertension (WSPH), one goal was to explore major issues regarding the pathobiology, diagnostic assessment, management, and outcomes of diverse childhood diseases associated with pediatric PH. There are marked differences in the epidemiology of pediatric and adult PH, as well as very striking differences in function, structure, genetics, and responsiveness to therapies between adults and children with PH. Unfortunately, studies that address the safety and efficacy of PH therapies in children are rare, as most pharmaceutical studies have focused on the adult population and only in patients with a fairly limited range of associated conditions. Except for the use of inhaled nitric oxide therapy for neonates with persistent PH of the newborn (PPHN) as based on multicenter randomized trials, nearly all of the current therapies for children remain almost exclusively based on results from adult clinical trials and small case series of the use of PH-targeted therapies. Thus, pediatric PH has been understudied, and little is understood regarding the natural history, mechanisms of disease, and treatment of childhood PH, especially in the setting of neonatal and genetic developmental lung diseases.","PeriodicalId":92747,"journal":{"name":"Advances in pulmonary hypertension","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42961269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
PH Professional Network: Bridging the Gap: A Multidisciplinary Approach to Transitions of Care PH专业网络:弥合差距:护理过渡的多学科方法
Advances in pulmonary hypertension Pub Date : 2019-11-27 DOI: 10.21693/1933-088x-18.3.103
S. McDevitt, C. Walter
{"title":"PH Professional Network: Bridging the Gap: A Multidisciplinary Approach to Transitions of Care","authors":"S. McDevitt, C. Walter","doi":"10.21693/1933-088x-18.3.103","DOIUrl":"https://doi.org/10.21693/1933-088x-18.3.103","url":null,"abstract":"INTRODUCTION Pulmonary hypertension (PH) is a chronic, progressive heterogeneous disease that affects many individuals worldwide. Despite extensive research and therapeutic advances in the treatment of PH, the morbidity and mortality rates remain high, and this bears a significant economic burden on the health care system. PH-related morbidity is associated with disease progression and often requires hospitalization, which may be considered an important measure of clinical worsening. Current US third-party reimbursement systems can penalize hospitals for hospital readmission. A coordinated multidisciplinary approach to hospital discharge is required for patients with PH.","PeriodicalId":92747,"journal":{"name":"Advances in pulmonary hypertension","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44545529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary Hypertension Due to Left Heart Disease—Combine or Not Combined? DPG In or Out? A Practical Approach to the Patient With Suspected Left Heart Disease 左心肺动脉高压——合并还是不合并?DPG输入还是输出?疑似左心病人的实用治疗方法
Advances in pulmonary hypertension Pub Date : 2019-11-27 DOI: 10.21693/1933-088x-18.3.87
T. Thenappan
{"title":"Pulmonary Hypertension Due to Left Heart Disease—Combine or Not Combined? DPG In or Out? A Practical Approach to the Patient With Suspected Left Heart Disease","authors":"T. Thenappan","doi":"10.21693/1933-088x-18.3.87","DOIUrl":"https://doi.org/10.21693/1933-088x-18.3.87","url":null,"abstract":"Pulmonary hypertension (PH) due to left heart disease (LHD) is the most common cause of PH in clinical practice. The definition and classification of PH-LHD has evolved in the last 5 years from the 5th World Symposium on PH (WSPH) in 2013 to the most recent 6th WSPH in 2018. Differentiation of PH-LHD, especially PH due to heart failure with preserved ejection from pulmonary arterial hypertension and chronic thromboembolic PH, can be very challenging. Finally, there is unclarity on the role of pulmonary vasodilators in the treatment of PH-LHD. The 6th WSPH consensus proceedings addresses all these topics in a detailed manner. In this article, we review the changes proposed by the 6th WSPH consensus proceedings in the definition, classification, diagnostic evaluation, and treatment of PH-LHD.","PeriodicalId":92747,"journal":{"name":"Advances in pulmonary hypertension","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48779389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Pulmonary Hypertension Roundtable: Behind the Scenes at the World Symposium on PH 2018 肺动脉高压圆桌会议:2018年世界PH研讨会的幕后
Advances in pulmonary hypertension Pub Date : 2019-11-01 DOI: 10.21693/1933-088x-18.3.97
{"title":"Pulmonary Hypertension Roundtable: Behind the Scenes at the World Symposium on PH 2018","authors":"","doi":"10.21693/1933-088x-18.3.97","DOIUrl":"https://doi.org/10.21693/1933-088x-18.3.97","url":null,"abstract":"","PeriodicalId":92747,"journal":{"name":"Advances in pulmonary hypertension","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46416255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk Stratification—What's My Risk? A Practitioner's Tool 风险分层——我的风险是什么?从业者的工具
Advances in pulmonary hypertension Pub Date : 2019-11-01 DOI: 10.21693/1933-088x-18.3.84
I. Preston
{"title":"Risk Stratification—What's My Risk? A Practitioner's Tool","authors":"I. Preston","doi":"10.21693/1933-088x-18.3.84","DOIUrl":"https://doi.org/10.21693/1933-088x-18.3.84","url":null,"abstract":"At the 6th World Symposium on Pulmonary Hypertension, the task force on clinical risk stratification and medical therapy in pulmonary arterial hypertension (PAH) reviewed the latest developments published in the field of therapeutics since the previous meeting and presented their consensus opinions to an audience of 1376 participant attendees between February 27 and March 1, 2018, in Nice, France. After participants’ input was incorporated, the final recommendations were published in the European Respiratory Journal. In the past several years, treatment for PAH was based on several parameters to determine the severity of the disease and risk of progression and poor outcome. These parameters included New York Heart Association Functional Class (NYHA FC), exercise capacity represented by the 6-minute walk distance (6MWD), and echocardiographic and hemodynamic measurements. Until recently, the guidelines for initiation and escalation of therapy relied mostly upon NYHA FC. However, data from 3 independent registries demonstrate the importance of a methodical risk assessment and treatment strategy in PAH patients. All registries prove that, in order to obtain a good outcome (assessed as event-free survival at 1 year), patients need to achieve a low-risk status.","PeriodicalId":92747,"journal":{"name":"Advances in pulmonary hypertension","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45902064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemodynamic Definitions and Updated Classification—Impact on Clinical Practice: A Conversation With Erika Berman Rosenzweig and Nicholas Hill 血液动力学定义和更新的分类——对临床实践的影响——与Erika Berman Rosenzweig和Nicholas Hill的对话
Advances in pulmonary hypertension Pub Date : 2019-11-01 DOI: 10.21693/1933-088x-18.3.80
{"title":"Hemodynamic Definitions and Updated Classification—Impact on Clinical Practice: A Conversation With Erika Berman Rosenzweig and Nicholas Hill","authors":"","doi":"10.21693/1933-088x-18.3.80","DOIUrl":"https://doi.org/10.21693/1933-088x-18.3.80","url":null,"abstract":"","PeriodicalId":92747,"journal":{"name":"Advances in pulmonary hypertension","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46538937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Exercise Pathophysiology in Pulmonary Arterial Hypertension—The Physiologic Explanation for Why Pulmonary Arterial Hypertension Does What It Does 肺动脉高压的运动病理生理——肺动脉高压的生理解释
Advances in pulmonary hypertension Pub Date : 2019-07-29 DOI: 10.21693/1933-088X-18.2.42
D. Dumitrescu, R. Oudiz
{"title":"Exercise Pathophysiology in Pulmonary Arterial Hypertension—The Physiologic Explanation for Why Pulmonary Arterial Hypertension Does What It Does","authors":"D. Dumitrescu, R. Oudiz","doi":"10.21693/1933-088X-18.2.42","DOIUrl":"https://doi.org/10.21693/1933-088X-18.2.42","url":null,"abstract":"Pulmonary arterial hypertension (PAH) is a chronic disease that is associated with a significant and progressive limitation of exercise tolerance. The pathophysiological mechanisms of exercise intolerance during exercise are complex, multifactorial, and in fact not limited to the pulmonary circulation and the right ventricle. Disturbance of autonomic nervous function leads to an enhanced chemosensitivity, as well as respiratory and peripheral muscle weakness, and systemic endothelial dysfunction, which together play important roles in PAH pathophysiology and symptomatology. This article is focused on the different pathophysiological mechanisms of exercise intolerance in PAH, their interactions, and their relevance for clinical practice.","PeriodicalId":92747,"journal":{"name":"Advances in pulmonary hypertension","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42760214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信